Stay updated with breaking news from Robertj Pignolo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Drug Application granted Priority Review status, with a decision anticipated on 30 November 2021 European Medicines Agency and Swissmedic have also validated...
Disclaimer: Intended for international media and investor audiences only Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP) New Drug Application granted Priority Review status, with a decision anticipated on 30 November 2021 Authorization Application (MAA) for palovarotene with Swissmedic granting palovarotene a priority review PARIS, FRANCE, 28 May 2021 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its New Drug ...
New Drug Application granted Priority Review status, with a decision anticipated on 30 November 2021 European Medicines Agency (EMA) and Swissmedic have also validated the Marketing Authorization